Etoposide Actavis 20 mg /ml concentrate for solution for infusion България - български - Изпълнителна агенция по лекарствата

etoposide actavis 20 mg /ml concentrate for solution for infusion

actavis group ptc ehf. - Этопозид - 20 mg /ml concentrate for solution for infusion

Etoposide Accord 20 mg/ml concentrate for solution for infusion България - български - Изпълнителна агенция по лекарствата

etoposide accord 20 mg/ml concentrate for solution for infusion

accord healthcare limited - Этопозид - 20 mg/ml concentrate for solution for infusion

Etoposide Ebewe 20 mg/ml concentrate for solution for infusion България - български - Изпълнителна агенция по лекарствата

etoposide ebewe 20 mg/ml concentrate for solution for infusion

ebewe pharma ges.m.b.h. nfg.kg - Этопозид - 20 mg/ml concentrate for solution for infusion

Etosid 20 mg/ml solution for infusion България - български - Изпълнителна агенция по лекарствата

etosid 20 mg/ml solution for infusion

cipla (uk) limited - Этопозид - 20 mg/ml solution for infusion

Tecentriq Европейски съюз - български - EMA (European Medicines Agency)

tecentriq

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - Антинеопластични средства - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq като монотерапии е предназначен за лечение на възрастни пациенти с локално-напреднал или метастазирал НМРЛ след като по-рано химиотерапия. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq като монотерапии е предназначен за лечение на възрастни пациенти с локално-напреднал или метастазирал НМРЛ след като по-рано химиотерапия. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Imfinzi Европейски съюз - български - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

TYLOSIN 20 % 200 mg/ml България - български - БАБХ (Българска агенция по безопасност на храните)

tylosin 20 % 200 mg/ml

alfasan international b.v - tylosine (като тартрат) - инжекционен разтвор - 200 mg/ml - говеда, котки, кучета, прасета

TYLOSIN 100 PREMIX 10 g/100 g България - български - БАБХ (Българска агенция по безопасност на храните)

tylosin 100 premix 10 g/100 g

Фарма СИС БГ ООД - Активността на тилозина (под формата на фосфат тилозина) - премикс за медикаментозен фураж - 10 g/100 g - свине

TYLOSIN 50 % WSP 500 000 IU/g България - български - БАБХ (Българска агенция по безопасност на храните)

tylosin 50 % wsp 500 000 iu/g

Завет АД - tartarate тилозин - прах за прилагане във вода за пиене - 500 000 iu/g - бройлери, прасета, птици, пуйки, свине

TYLOSIN 60 % BG 60 g/100 g България - български - БАБХ (Българска агенция по безопасност на храните)

tylosin 60 % bg 60 g/100 g

s.c. crida pharm s.r.l. - Тилозин тартрат - прах за прилагане във вода за пиене - 60 g/100 g - бройлери, свине